Drug Profile
DFN 529
Alternative Names: DFN-529; P 529; P 52901; Palomid 529; Palomids; RES-529; SG-00529Latest Information Update: 17 Aug 2023
Price :
$50
*
At a glance
- Originator Paloma Pharmaceuticals
- Developer CervoMed; National Cancer Institute (USA)
- Class Antiepileptic drugs; Antifibrotics; Antineoplastics; Antipsoriatics; Chromans; Eye disorder therapies; Skin disorder therapies; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis stimulants; Hypoxia-inducible factor 1 inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors; Proto oncogene protein c-akt inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Atopic dermatitis; Breast cancer; Cancer; Diabetic retinopathy; Epilepsy; Glioblastoma; Proliferative vitreoretinopathy; Prostate cancer; Psoriasis; Pulmonary fibrosis; Rosacea; Scars